Sera Prognostics, Inc.
SERAHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeSera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The $80.1M market capitalization puts SERA squarely in micro-cap range for its industry. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Market Cap
$80.1M
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
-3.79
EPS (TTM)
$-0.67
EPS (Fwd)
$-0.54
ROE
-45.0%
ROA
-23.5%
Cash
$46.4M
Total Debt
$3.0M
Free CF
-$18.9M
52W Change
-45.7%
Annual Financials
Cash vs Debt
Where SERA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SERA finished 1.00% above its 150-day moving average ($2.01) and 7.31% below its 200-day moving average ($2.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SERA overbought or oversold?
At the October 20, 2026 close, SERA's RSI(14) was 51.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Sera Prognostics, Inc. holds $46.4M in cash against $3.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$18.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -45.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $268K to $81K.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sera Prognostics, Inc.'s trajectory.